These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 31401389)

  • 41. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease.
    Chavez-Tapia NC; Rosso N; Tiribelli C
    BMC Gastroenterol; 2012 Mar; 12():20. PubMed ID: 22380754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stearate-to-palmitate ratio modulates endoplasmic reticulum stress and cell apoptosis in non-B non-C hepatoma cells.
    Shibasaki Y; Horikawa M; Ikegami K; Kiuchi R; Takeda M; Hiraide T; Morita Y; Konno H; Takeuchi H; Setou M; Sakaguchi T
    Cancer Sci; 2018 Apr; 109(4):1110-1120. PubMed ID: 29427339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [ER stress and NAFLD].
    Lachkar F; Papaioannou A; Ferré P; Foufelle F
    Biol Aujourdhui; 2020; 214(1-2):15-23. PubMed ID: 32773026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
    Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.
    Wu H; Ng R; Chen X; Steer CJ; Song G
    Gut; 2016 Nov; 65(11):1850-1860. PubMed ID: 26282675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new perspective on NAFLD: Focusing on lipid droplets.
    Scorletti E; Carr RM
    J Hepatol; 2022 Apr; 76(4):934-945. PubMed ID: 34793866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth.
    Dashti Z; Yousefi Z; Kiani P; Taghizadeh M; Maleki MH; Borji M; Vakili O; Shafiee SM
    Metabolism; 2024 May; 154():155811. PubMed ID: 38309690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NAFLD-related HCC.
    Banini BA; Sanyal AJ
    Adv Cancer Res; 2021; 149():143-169. PubMed ID: 33579423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease.
    Chen CC; Hsu LW; Chen KD; Chiu KW; Chen CL; Huang KT
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
    J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
    Zhang Y; Wang H; Xiao H
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.
    Lee J; Park JS; Roh YS
    Arch Pharm Res; 2019 Nov; 42(11):935-946. PubMed ID: 31571145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
    Khare T; Khare S; Angdisen JJ; Zhang Q; Stuckel A; Mooney BP; Ridenhour SE; Gitan RS; Hammoud GM; Ibdah JA
    Int J Cancer; 2020 Sep; 147(5):1461-1473. PubMed ID: 32115688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
    Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic loss of
    Li X; Liu L; Li R; Wu A; Lu J; Wu Q; Jia J; Zhao M; Song H
    J Biol Chem; 2018 Apr; 293(14):5160-5171. PubMed ID: 29475944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protective effect of the Y220C mutant p53 against steatosis: good news?
    Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
    J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bnip3 in mitophagy: Novel insights and potential therapeutic target for diseases of secondary mitochondrial dysfunction.
    Gao A; Jiang J; Xie F; Chen L
    Clin Chim Acta; 2020 Jul; 506():72-83. PubMed ID: 32092316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma.
    Li T; Weng J; Zhang Y; Liang K; Fu G; Li Y; Bai X; Gao Y
    Cell Death Dis; 2019 Aug; 10(8):619. PubMed ID: 31409773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.